Anti-Reflux Surgery Promising in Idiopathic Pulmonary Fibrosis

Share this content:
In phase 2 study, surgery for abnormal acid GER in IPF patients was safe, well-tolerated.
In phase 2 study, surgery for abnormal acid GER in IPF patients was safe, well-tolerated.

HealthDay News — Laparoscopic antireflux surgery is safe and well-tolerated in patients with idiopathic pulmonary fibrosis (IPF) and abnormal acid gastroesophageal reflux (GER), according to a phase 2 study published in the Sept. 1 issue of The Lancet Respiratory Medicine.

Ganesh Raghu, MD, from the University of Washington in Seattle, and colleagues performed a randomized controlled trial to assess whether treatment of abnormal acid GER with laparoscopic antireflux surgery reduced the rate of disease progression among 29 patients with IPF and abnormal acid GER recruited from 6 US academic centers vs those not receiving surgery (29 patients).

After adjusting for baseline anti-fibrotic use in an intention-to-treat analysis, the researchers found that the rate of change in forced vital capacity over 48 weeks was −0.05 L (95% confidence interval, −0.15 to 0.05) in the surgery group and −0.13 L (95% confidence interval, −0.23 to −0.02) in the non-surgery group (P = 0.28). In the surgery group, acute exacerbation, respiratory-related hospitalization, and death were less common without statistical significance. The most common adverse events after surgery included dysphagia (29%) and abdominal distention (14%). In addition, there was one death in the surgery group and 4 deaths in the non-surgery group.

"A larger, well-powered, randomized controlled study of antireflux surgery is needed in this population," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial (subscription or payment may be required)

You must be a registered member of Clinical Advisor to post a comment.

Next Article in Gastroenterology Information Center

Sign Up for Free e-newsletters